Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus.

Linnstaedt SD, Gottwein E, Skalsky RL, Luftig MA, Cullen BR.

J Virol. 2010 Nov;84(22):11670-8. doi: 10.1128/JVI.01248-10. Epub 2010 Sep 15.

2.

The Epstein-Barr virus (EBV)-induced tumor suppressor microRNA MiR-34a is growth promoting in EBV-infected B cells.

Forte E, Salinas RE, Chang C, Zhou T, Linnstaedt SD, Gottwein E, Jacobs C, Jima D, Li QJ, Dave SS, Luftig MA.

J Virol. 2012 Jun;86(12):6889-98. doi: 10.1128/JVI.07056-11. Epub 2012 Apr 11.

3.

NF-κB directly mediates epigenetic deregulation of common microRNAs in Epstein-Barr virus-mediated transformation of B-cells and in lymphomas.

Vento-Tormo R, Rodríguez-Ubreva J, Lisio LD, Islam AB, Urquiza JM, Hernando H, López-Bigas N, Shannon-Lowe C, Martínez N, Montes-Moreno S, Piris MA, Ballestar E.

Nucleic Acids Res. 2014;42(17):11025-39. doi: 10.1093/nar/gku826. Epub 2014 Sep 8.

4.

The viral and cellular microRNA targetome in lymphoblastoid cell lines.

Skalsky RL, Corcoran DL, Gottwein E, Frank CL, Kang D, Hafner M, Nusbaum JD, Feederle R, Delecluse HJ, Luftig MA, Tuschl T, Ohler U, Cullen BR.

PLoS Pathog. 2012 Jan;8(1):e1002484. doi: 10.1371/journal.ppat.1002484. Epub 2012 Jan 26.

5.

EBV-miR-BHRF1-2 targets PRDM1/Blimp1: potential role in EBV lymphomagenesis.

Ma J, Nie K, Redmond D, Liu Y, Elemento O, Knowles DM, Tam W.

Leukemia. 2016 Mar;30(3):594-604. doi: 10.1038/leu.2015.285. Epub 2015 Nov 4.

6.

Re-expression of microRNA-150 induces EBV-positive Burkitt lymphoma differentiation by modulating c-Myb in vitro.

Chen S, Wang Z, Dai X, Pan J, Ge J, Han X, Wu Z, Zhou X, Zhao T.

Cancer Sci. 2013 Jul;104(7):826-34. doi: 10.1111/cas.12156. Epub 2013 Apr 28.

7.

Regulation of the MIR155 host gene in physiological and pathological processes.

Elton TS, Selemon H, Elton SM, Parinandi NL.

Gene. 2013 Dec 10;532(1):1-12. doi: 10.1016/j.gene.2012.12.009. Epub 2012 Dec 14. Review.

PMID:
23246696
8.

Steps involved in immortalization and tumorigenesis in human B-lymphoblastoid cell lines transformed by Epstein-Barr virus.

Sugimoto M, Tahara H, Ide T, Furuichi Y.

Cancer Res. 2004 May 15;64(10):3361-4. Review.

9.

hTERT inhibition triggers Epstein-Barr virus lytic cycle and apoptosis in immortalized and transformed B cells: a basis for new therapies.

Giunco S, Dolcetti R, Keppel S, Celeghin A, Indraccolo S, Dal Col J, Mastorci K, De Rossi A.

Clin Cancer Res. 2013 Apr 15;19(8):2036-47. doi: 10.1158/1078-0432.CCR-12-2537. Epub 2013 Feb 26.

10.

Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) induces the expression of the cellular microRNA miR-146a.

Motsch N, Pfuhl T, Mrazek J, Barth S, Grässer FA.

RNA Biol. 2007 Nov;4(3):131-7.

PMID:
18347435
11.

Epstein-Barr virus growth/latency III program alters cellular microRNA expression.

Cameron JE, Fewell C, Yin Q, McBride J, Wang X, Lin Z, Flemington EK.

Virology. 2008 Dec 20;382(2):257-66. doi: 10.1016/j.virol.2008.09.018. Epub 2008 Oct 31.

12.

Analysis of the mRNA targetome of microRNAs expressed by Marek's disease virus.

Parnas O, Corcoran DL, Cullen BR.

MBio. 2014 Jan 21;5(1):e01060-13. doi: 10.1128/mBio.01060-13.

13.

The Epstein-Barr virus BamHI C promoter is not essential for B cell immortalization in vitro, but it greatly enhances B cell growth transformation.

Tierney RJ, Nagra J, Rowe M, Bell AI, Rickinson AB.

J Virol. 2015 Mar;89(5):2483-93. doi: 10.1128/JVI.03300-14. Epub 2014 Dec 24.

14.

Dynamic Epstein-Barr virus gene expression on the path to B-cell transformation.

Price AM, Luftig MA.

Adv Virus Res. 2014;88:279-313. doi: 10.1016/B978-0-12-800098-4.00006-4. Review.

15.

MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival.

Forte E, Luftig MA.

J Virol. 2009 Mar;83(6):2491-9. doi: 10.1128/JVI.01681-08. Epub 2009 Jan 14.

16.

EBV transformation overrides gene expression patterns of B cell differentiation stages.

Siemer D, Kurth J, Lang S, Lehnerdt G, Stanelle J, Küppers R.

Mol Immunol. 2008 Jun;45(11):3133-41. doi: 10.1016/j.molimm.2008.03.002. Epub 2008 Apr 21.

PMID:
18430472
17.

Oncogenic IRFs provide a survival advantage for Epstein-Barr virus- or human T-cell leukemia virus type 1-transformed cells through induction of BIC expression.

Wang L, Toomey NL, Diaz LA, Walker G, Ramos JC, Barber GN, Ning S.

J Virol. 2011 Aug;85(16):8328-37. doi: 10.1128/JVI.00570-11. Epub 2011 Jun 15.

18.

Cytokine signatures of transformed B cells with distinct Epstein-Barr virus latencies as a potential diagnostic tool for B cell lymphoma.

Miyauchi K, Urano E, Yoshiyama H, Komano J.

Cancer Sci. 2011 Jun;102(6):1236-41. doi: 10.1111/j.1349-7006.2011.01924.x. Epub 2011 Apr 1.

19.

Epstein-Barr virus (EBV) and lymphomagenesis.

Cesarman E.

Front Biosci. 2002 Feb 1;7:e58-65. Review.

PMID:
11815280
20.

A viral microRNA cluster strongly potentiates the transforming properties of a human herpesvirus.

Feederle R, Linnstaedt SD, Bannert H, Lips H, Bencun M, Cullen BR, Delecluse HJ.

PLoS Pathog. 2011 Feb;7(2):e1001294. doi: 10.1371/journal.ppat.1001294. Epub 2011 Feb 17.

Supplemental Content

Support Center